![]() | |
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | 98% |
Eliminationhalf-life | 9-14 hours |
Identifiers | |
| |
CAS Number | |
PubChemCID | |
ChemSpider |
|
UNII | |
KEGG |
|
ChEMBL | |
CompTox Dashboard(EPA) | |
Chemical and physical data | |
Formula | C14H16BrNO2 |
Molar mass | 310.191 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Brofaromine (proposed brand nameConsonar) is areversible inhibitor of monoamine oxidase A (RIMA) discovered by Ciba-Geigy.[1] The compound was primarily researched in the treatment ofdepression andanxiety but its development was dropped before it was brought to market.[2]
Brofaromine also acts as aserotonin reuptake inhibitor, and its dual pharmacologic effects offered promise in the treatment of a wide spectrum of depressed patients while producing less severeanticholinergic side effects in comparison with older standard drugs like certain of thetricyclic antidepressants.
Brofaromine is areversible inhibitor of monoamine oxidase A (RIMA, a type ofmonoamine oxidase inhibitor (MAOI)) and acts onepinephrine (adrenaline),norepinephrine (noradrenaline),serotonin, anddopamine. Unlike standard MAOIs, possible side effects do not includecardiovascular complications (hypertension) withencephalopathy,liver toxicity orhyperthermia.
![]() | This article about ananxiolytic is astub. You can help Wikipedia byexpanding it. |